| IVM | Ivermectin |
| COVID-19 | Coronavirus disease of 2019 |
| FDA | United States Food and Drug Administration |
| WHO | World Health Organization |
| NIH | National Institutes of Health |
| GIT | Gastrointestinal tract |
| SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 |
| ACE2 | Angiotensin-converting enzyme 2 |
| TMPRSS2 | Transmembrane protease, serine 2 |
| ROS | Reactive oxygen species |
| 3CLpro | 3-Chymotrypsin-like Protease |
| HIF-1α | Hypoxia-inducible factor 1-alpha |
| Vero/hSLAM cells | Vero cells strongly expressing human signaling lymphocyte activation molecules |
| HDA | Host-directed agent |
| RNA | Ribonucleic acid |
| IMP | Importin |
| HIV-1 | Human immunodeficiency virus type 1 |
| HAdV | Human adenovirus |
| BoAHV-1 | Varicellovirus bovinealpha 1 |
| MDBK | Madin-Darby Bovine Kidney |
| BT | Bovine turbinate |
| STD | Sexually transmitted disease |
| MIC | Minimum inhibitory concentration |
| DNA | Deoxyribonucleic acid |
| M. ulcerans | Mycobacterium ulcerans |
| S. aureus | Staphylococcus aureus |
| MRSA | Methicillin-resistant Staphylococcus aureus |
| MSSA | Methicillin-sensitive Staphylococcus aureus |
| CSCs | Cancer stem-like cells |
| WNT | Wingless signaling |
| TCF | T-cell factor |
| mTOR | Mammalian target of rapamycin |
| PAK1 | p21-activated kinase 1 |
| SID | Surface-induced dissociation |
| MDR | Multi-drug resistance |
| Bax | Bcl-2 associated X protein |
| HIF | Hypoxia-inducible factor |
| JNK | c-Jun N-terminal kinase |
| ERK 1/2 | Extracellular signal-regulated kinase 1 and 2 |
| NO | Nitric oxide |
| PGE2 | Prostaglandin E2 |
| NOS | Nitric oxide synthase |
| COX2 | Cyclooxygenase-2 |
| TGF-β1 | Transforming growth factor-beta 1 |
| VEGF | Vascular endothelial growth factor |
| FXR | Farnesoid X receptor |
| LD50 | Lethal dose 50% |
| w/w | Weight per weight |
| ABCB1 | ATP Binding Cassette Subfamily B Member 1 |
| P-gp | P-glycoprotein |
| ATP | Adenosine triphosphate |
| CNS | Central nervous system |
| ADME | Absorption, distribution, metabolism, and excretion |
| SLNs | Solid lipid nanoparticles |
| Hb | Hemoglobin |
| TLC | Total leucocyte count |
| DLC | Differential leucocyte count |
| BUN | Blood urea nitrogen |
| ALT | Alanine transaminase |
| AST | Aspartate transferase |
| Cmax | Peak plasma concentration |
| t½ | Elimination half-life |
| IV | Intravenous |
| Tmax | Duration/time to reach Cmax |
| SAHPRA | South African Health Product Regulatory Authority |
| HPLC | High-performance liquid chromatography |
| AUC | Analytical peak area |
| ODT(s) | Oral disintegrating tablet(s) |
| EC50 | Half maximal effective concentration |
| ED | Epidermis-dermis |
| SCE | Stratum corneum-epidermis |
| CYP | Cytochrome P |
| PNPs | Polymeric nanoparticles |
| NLCs | Nanostructured lipid carriers |
| SNEDDS | Self-nano-emulsifying drug delivery systems |
| PLGA | Poly(lactide-co-glycolide) |
| PEG | Polyethylene glycol |
| GMP | Good Manufacturing Practice |
| MSNs | Mesoporous silica nanoparticles |
| IVM-MCM | Ivermectin mesoporous silica particles |
| IVM-NC | Ivermectin poly(ε-caprolactone) nanocapsules |
| PEDV | Porcine epidemic diarrhea virus |
| C6 | Coumarin 6 |
| SEDDS | Self-emulsifying drug delivery systems |